JP2010531812A - モルヒネ及びトロパンアルカロイドのワンポットn−脱メチル化及びn−アシル化のための方法 - Google Patents
モルヒネ及びトロパンアルカロイドのワンポットn−脱メチル化及びn−アシル化のための方法 Download PDFInfo
- Publication number
- JP2010531812A JP2010531812A JP2010513588A JP2010513588A JP2010531812A JP 2010531812 A JP2010531812 A JP 2010531812A JP 2010513588 A JP2010513588 A JP 2010513588A JP 2010513588 A JP2010513588 A JP 2010513588A JP 2010531812 A JP2010531812 A JP 2010531812A
- Authority
- JP
- Japan
- Prior art keywords
- anhydride
- group
- dicarbonate
- catalyst
- morphine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 72
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title claims abstract description 29
- 238000010520 demethylation reaction Methods 0.000 title claims abstract description 17
- 229930013053 morphinan alkaloid Natural products 0.000 title claims abstract description 15
- 150000003813 tropane derivatives Chemical class 0.000 title claims abstract description 12
- 229930004668 tropane alkaloid Natural products 0.000 title claims abstract description 10
- 230000006181 N-acylation Effects 0.000 title claims abstract description 9
- 229960005181 morphine Drugs 0.000 title claims abstract description 9
- 238000005580 one pot reaction Methods 0.000 title claims abstract description 9
- 230000008569 process Effects 0.000 title claims description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 67
- 150000008064 anhydrides Chemical group 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 229910052763 palladium Inorganic materials 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- ZFTFAPZRGNKQPU-UHFFFAOYSA-N dicarbonic acid Chemical compound OC(=O)OC(O)=O ZFTFAPZRGNKQPU-UHFFFAOYSA-N 0.000 claims description 12
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 12
- 229960000240 hydrocodone Drugs 0.000 claims description 12
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 12
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical group COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 11
- 101150003085 Pdcl gene Proteins 0.000 claims description 11
- 239000004316 dimethyl dicarbonate Substances 0.000 claims description 11
- 235000010300 dimethyl dicarbonate Nutrition 0.000 claims description 11
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- -1 cyclopropylcarbonyl anhydride Chemical class 0.000 claims description 9
- 238000005917 acylation reaction Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 8
- QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 claims description 6
- 230000010933 acylation Effects 0.000 claims description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 6
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 6
- 229910052759 nickel Inorganic materials 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 229910052707 ruthenium Inorganic materials 0.000 claims description 6
- QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 claims description 6
- 229910052741 iridium Inorganic materials 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 229910052745 lead Inorganic materials 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052703 rhodium Inorganic materials 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 229910052718 tin Inorganic materials 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 4
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- NKAALORGDRIHOG-UHFFFAOYSA-N diphenylcarbamoyl n,n-diphenylcarbamate Chemical compound C=1C=CC=CC=1N(C=1C=CC=CC=1)C(=O)OC(=O)N(C=1C=CC=CC=1)C1=CC=CC=C1 NKAALORGDRIHOG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- FVTWJBIYEGCRNU-UHFFFAOYSA-N methyl 2-[(2-methoxy-2-oxoethyl)carbamoyloxycarbonylamino]acetate Chemical compound COC(=O)CNC(=O)OC(=O)NCC(=O)OC FVTWJBIYEGCRNU-UHFFFAOYSA-N 0.000 claims description 4
- 229960002085 oxycodone Drugs 0.000 claims description 4
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims description 4
- QWZPWKSAEPEWOP-UHFFFAOYSA-N pyrrole-1-carbonyl pyrrole-1-carboxylate Chemical compound C1=CC=CN1C(=O)OC(=O)N1C=CC=C1 QWZPWKSAEPEWOP-UHFFFAOYSA-N 0.000 claims description 4
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 4
- 229930004006 tropane Natural products 0.000 claims description 4
- VFNHLTBRAFJQER-ISWURRPUSA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(O)=CC=C1C4 VFNHLTBRAFJQER-ISWURRPUSA-N 0.000 claims description 3
- XQJMXPAEFMWDOZ-UHFFFAOYSA-N 3exo-benzoyloxy-tropane Natural products CN1C(C2)CCC1CC2OC(=O)C1=CC=CC=C1 XQJMXPAEFMWDOZ-UHFFFAOYSA-N 0.000 claims description 3
- ZWGIZHOZSXFSNW-UHFFFAOYSA-N 4-(2-oxo-1,3-dioxolan-4-yl)-1,3-dioxolan-2-one Chemical compound O1C(=O)OCC1C1OC(=O)OC1 ZWGIZHOZSXFSNW-UHFFFAOYSA-N 0.000 claims description 3
- QCMLOHSHCOOPQB-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenoxy]piperidin-1-ium;chloride Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1OC1CCNCC1 QCMLOHSHCOOPQB-UHFFFAOYSA-N 0.000 claims description 3
- 229930003347 Atropine Natural products 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 claims description 3
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 claims description 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 3
- QIZDQFOVGFDBKW-DHBOJHSNSA-N Pseudotropine Natural products OC1C[C@@H]2[N+](C)[C@H](C1)CC2 QIZDQFOVGFDBKW-DHBOJHSNSA-N 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
- 229960000396 atropine Drugs 0.000 claims description 3
- FHRRJZZGSJXPRQ-UHFFFAOYSA-N benzyl phenylmethoxycarbonyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OC(=O)OCC1=CC=CC=C1 FHRRJZZGSJXPRQ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 229960003920 cocaine Drugs 0.000 claims description 3
- 229960004126 codeine Drugs 0.000 claims description 3
- HTWWKYKIBSHDPC-UHFFFAOYSA-N decanoyl decanoate Chemical compound CCCCCCCCCC(=O)OC(=O)CCCCCCCCC HTWWKYKIBSHDPC-UHFFFAOYSA-N 0.000 claims description 3
- 125000000532 dioxanyl group Chemical group 0.000 claims description 3
- NWADXBLMWHFGGU-UHFFFAOYSA-N dodecanoic anhydride Chemical compound CCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCC NWADXBLMWHFGGU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052732 germanium Inorganic materials 0.000 claims description 3
- AABLHGPVOULICI-BRJGLHKUSA-N hydromorphinol Chemical compound O([C@H]1[C@H](CC[C@]23O)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O AABLHGPVOULICI-BRJGLHKUSA-N 0.000 claims description 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 3
- 229960001410 hydromorphone Drugs 0.000 claims description 3
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 claims description 3
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims description 3
- 150000003956 methylamines Chemical class 0.000 claims description 3
- JGORUXKMRLIJSV-ZWUPXRALSA-N norhydrocodone Chemical class O=C([C@H]1O2)CC[C@@H]3[C@@]4([H])NCC[C@@]13C1=C2C(OC)=CC=C1C4 JGORUXKMRLIJSV-ZWUPXRALSA-N 0.000 claims description 3
- 229960005118 oxymorphone Drugs 0.000 claims description 3
- OPVOKTZBUWENMY-UHFFFAOYSA-N phenylcarbamoyl n-phenylcarbamate Chemical compound C=1C=CC=CC=1NC(=O)OC(=O)NC1=CC=CC=C1 OPVOKTZBUWENMY-UHFFFAOYSA-N 0.000 claims description 3
- XVSSGIXTKVRGAR-UHFFFAOYSA-N prop-2-enoxycarbonyl prop-2-enyl carbonate Chemical compound C=CCOC(=O)OC(=O)OCC=C XVSSGIXTKVRGAR-UHFFFAOYSA-N 0.000 claims description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 claims description 3
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims description 3
- 229930003945 thebaine Natural products 0.000 claims description 3
- CYHOMWAPJJPNMW-JIGDXULJSA-N tropine Chemical compound C1[C@@H](O)C[C@H]2CC[C@@H]1N2C CYHOMWAPJJPNMW-JIGDXULJSA-N 0.000 claims description 3
- YYCRAERBSFHMPL-XFKAJCMBSA-N (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,7a,13-tetrahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one Chemical compound O=C([C@@H]1O2)C=C[C@@]3(O)[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 YYCRAERBSFHMPL-XFKAJCMBSA-N 0.000 claims description 2
- YYCRAERBSFHMPL-UHFFFAOYSA-N 14beta-Hydroxycodeinone Natural products O1C2C(=O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YYCRAERBSFHMPL-UHFFFAOYSA-N 0.000 claims description 2
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 claims description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- NPJDHGWEVPHWHE-ZVLVQXPOSA-N (4R,4aR,7aR,12bS)-11-(cyclopropanecarbonyl)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound C1(CC1)C(=O)C1=CC(O)=C2C=3[C@@]45[C@@H](O2)C(=O)CC[C@H]4[C@@H](CC1=3)N(C)CC5 NPJDHGWEVPHWHE-ZVLVQXPOSA-N 0.000 description 2
- RDOSKYXGGWCNCJ-UHFFFAOYSA-N 4-oxo-4-(3-oxo-8-azabicyclo[3.2.1]octan-8-yl)butanoic acid Chemical compound C1C(=O)CC2CCC1N2C(=O)CCC(=O)O RDOSKYXGGWCNCJ-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000006972 Polonovski rearrangement reaction Methods 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000021523 carboxylation Effects 0.000 description 2
- 238000006473 carboxylation reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- OJHZNMVJJKMFGX-BWCYBWMMSA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 description 1
- YPZPXTZKBNWUTF-QMVVXIJUSA-N (4r,4as,7s,7ar,12bs)-9-methoxy-3-methyl-1,2,4,7,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7-diol Chemical compound O[C@H]([C@@H]1O2)C=C[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C YPZPXTZKBNWUTF-QMVVXIJUSA-N 0.000 description 1
- YPZPXTZKBNWUTF-UHFFFAOYSA-N 14beta-Hydroxy-codein Natural products O1C2C(O)C=CC3(O)C4CC5=CC=C(OC)C1=C5C23CCN4C YPZPXTZKBNWUTF-UHFFFAOYSA-N 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- ORTDZGFNIQBSPY-UHFFFAOYSA-N CCC[N](C)(C)C Chemical compound CCC[N](C)(C)C ORTDZGFNIQBSPY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 229910052766 Lawrencium Inorganic materials 0.000 description 1
- IHBSVVZENGBQDY-BBWFWOEESA-N N-Methyl morphinan Chemical compound C1C2=CC=CC=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 IHBSVVZENGBQDY-BBWFWOEESA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- JGORUXKMRLIJSV-UHFFFAOYSA-N Norhydrocodone Natural products O1C2C(=O)CCC3C4CC5=CC=C(OC)C1=C5C23CCN4 JGORUXKMRLIJSV-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000006274 oxidative n-demethylation reaction Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
【解決手段】本発明は、モルヒネアルカロイドまたはトロパンアルカロイドのような第三級N−メチル化ヘテロ環のN−脱メチル化及び/又はN−アシル化のためのワンポット法に関する。スキームIで例示される該方法は、Pd触媒存在下、前記第三級N−メチル化ヘテロ環とアシル化試薬と反応することを含む。
【選択図】なし
Description
不飽和種をうまく利用するが、しかしながら、α,β−不飽和ケトンを含む化合物はそれらのマイケルアクセプターの特性のために、潜在的な遺伝毒性物質であると最近確認されており、そしてそれ故、これらの中間体を避ける、酸素化された誘導体への新しいルートを発見することが望まれている。
の化学の研究は、モルヒネ誘導体の生産のための新しい方法の必要性に対処する本発明につながる。本発明は、費用効率が高く安全な、モルヒネアルカロイドのワンポット酸化的N−脱メチル化及びそれに続くN−アシル化のための条件を解明する。
)2、Pd(PPh3)4、Cu、Fe、Ru、Co、Rh、Ir、Ni、Pd、Pt、G
e、Sn、Os、Cu、Ag、Au、Pbから成る群から選択される金属触媒である。
ーボネートである。
ら選択される。
OAc)2、Pd(PPh3)4及びPd(dba)2などのパラジウム触媒である。好ましい実施態様においてパラジウム触媒はPd(OAc)2である。
れは、N−メトキシカルボニルノルヒドロコドン8の生成をもたらす。
実施例1.脱メチル化/アシル化のための一般的な手順
時間加熱し、室温まで冷却し、そして溶離剤として80:20:1のCHCl3:MeO
H:NH4OHを使用したシリカのプラグを通過させた。揮発性物質を真空で除去し、そ
して残渣をNaHCO3中に懸濁した。水層をCHCl3で抽出し、そして1Mの塩酸で洗浄した有機物の抽出物と組み合わせ、そして硫酸マグネシウムで乾燥する前に塩水につけ、濾過及び揮発性物質を真空で除去し、アシル生成物を生成した。
用を含む。
実施例1a乃至1j.ヒドロコドン(3)のN−脱メチル化−アシル化
,1628,1505,1436,1325,1274,1241,1121,1061,1026 1H NMR(CDCl3,600MHz):6.77(d,J=8.2Hz,1H),6.68(d,J=8.2Hz,1H),5.25−5.28(m,1H),4.69(s,1H),3.94(s,3H),3.67(dd,J=13.8,4.8Hz,1H),3.09(dt,J=13.2,4.0Hz,1H),2.91(dd,J=18.6,6.1Hz,1H),2.67(d,J=18.6,6.1Hz,1H),2.32−2.51(m,3H),2.14(s,3H),1.91−2.02(m,3H),1.20−1.32(m,1H)ppm、13C NMR(CDCl3,125M
Hz):206.8,169.0,145.6,143.2,126.0,124.9,120.4,115.1,91.0,56.8,47.6,47.3,41.2,40.5,39.9,35.5,28.4,25.3,22.1ppm、MS(EI)m/z(%)327(24),241(23),117(10),87(68),86(21),85(72),84 9(31),83(100),57(12),49(13),48(12),47(28),43(23),41(10)、HRMS C19H21NO4とし
ての計算値:327.1470,実測値327.1483。
MHz):206.7,168.7,145.6,143.6,126.0,123.9,120.3,115.3,91.0,56.8,53.8,47.2,42.1,39.7,35.4,34.7,29.2,25.5,21.9ppm MS(EI)m/z(%)327(24),241(23),117(10),87(68),86(21),85(72),84(31),83(100),57(12),49(13),48(12),47(28),43(23),41(10)HRMS C19H21NO4としての
計算値:327.1470, 実測値327.1483.
実施例2:無水物の系列の反応性
実施例1に概要を述べた一般的な手順に続いて、無水物の系列の反応性を調査した。
2933,1728,1643,1634,1505,1435,1327,1276,1260,1177,1156,1032,958,754、 1H NMR (CDC
l3, 300MHz): 6.77(d,J=8.2Hz,1H),6.68(d,J
=8.6Hz,1H),5.26 −5.33(m, 1H),4.68(s,1H),3.94(S,3H),3.74−3.84 (m, 1H),2.73−3.12(m,3H),2.62(d,J=18.5Hz,1 H),2.28−2.51(m,3H),1.87−2.06(m,3H),1.20−1.30(m,1H),1.19(d,J=6.8Hz,3H),1.12 (d,J=7.02Hz,3H)、13C NMR(CDCl3,75.5MHz): 206.92,175.35,145.57,14
3.18,126.18,125.08,120.36,115.13,90.97,56.78,47.61,47.39,41.38,39.92,39.35,35.86,30.46,28.45,25.35,19.62,19.08、MS(El)m/z(%): 355(34.5),242(12.5),241(33.7),115(98.6),100(12.5),88(12.7),87(16.0),86(65.9), 84(100.0),72(23.7),55(10.7),49(19.5),47(23.7),43(52.9),41(15.1)、HRMS(El)C21H25NO4としての計算値: 355.1784、実測値 355.1777。
,1631,1505,1438,1327,1275,1115,960,753(メジャー異性体)1H NMR(CDCl3,600MHz):6.76(d,J=8.2Hz,1H),6.64−6.70(m,1H),5.22−5.26(m,1H),4.69(s,1H),4.09(dd,J=13.7,4.6Hz,1H),3.92(s,3H),3.12(dt,J=13.2,3.7Hz,1H),2.89(dd,J=18.3,6.2Hz,1H),2.65(d,J=18.5Hz,1H),2.31−2.63(m,5H),2.04(dt,J=12.5,5.1Hz,1H),1.89−2.00(m,1H),1.70−1.78(m,1H),1.18−1.36(m,1H),0.96−1.09(m,1H),0.74−0.92(m,2H)13C NMR(CDCl3, 150MHz):207.1,172.0,145.6,143.3
,126.2, 125.1,120.4,115.1,91.1,67.1,56.7,48.3,47.4,42.1,39.9,36.2,29.7,28.4,11.5, 8.8,7.6(マイナー異性体) 1H NMR(CDCl3,600MHz): 6.76(d,J=8.2Hz,1H),6.64−6.70(m,1H),4.73−4.77(m,1H),4.70(s,1H),4.50(dd,J=13.9,3.6Hz,1H),3.92(s,3H),2.99(dd,J=18.0, 5.7Hz,1H),2.80(d,J=18.1Hz,1H),2.31−2.63(m,5H),2.04(dt,J=12.5,5.1Hz,1H),1.89−2.00(m,1H),1.81−1.83(m,1H),1.57−1.65(m,1H),1.18−1.36(m,1H),0.96−1.09(m,1 H),0.74−0.92(m,2H)13C NMR(CDCl3,150MHz): 206.9,171.9,145.5
,143.1,126.2,125.1, 120.2,114.9,91.0,67.1,56.7,48.3,47.4, 41.2,39.7,35.7,29.4,25.3,11.5,7.5,7.3 MS(El)m/z(%):354(17),353(66),301(28), 300(11),242(30),241(57),240(14),213(11),199(11),185(19),164(30),14
1(10),129(16),128(12),127(10),115(15),114(11),113(61),112(82),111(28),109(11),99(11),98(73),97(11),88(23),87(19),86(48),85(89),84(80),83(100),82(18),72(13),71(21),70(25),69(81),68(14),60(12),59(18),58(22),57(37),56(13),55(31),49(21),48(13),47(36),45(22),44(28),43(40),42(32),41(77) HRMS(El)C21H23NO4としての計算値:353.1627、 実測値35
3.1612。
49,1727,1634,1505,1437,1276,1118,1031,971 1H NMR(CDCl3,600 MHz):6.68 (d,J=8.2Hz,1H),6.59(d,J=8.3Hz,1H),5.17−5.22(m,1H),4.60(s,1H),3.85(s,3H),3.62(dd,J=13.4,5.0Hz,1H),2.96(dt,J=13.0, 3.8Hz,1H),2.83(dd,J=18.6,6.0 Hz,1H),2.56(d,J=8.5Hz,1H),2.20−2.47(m,6H),1.81−1.93(m,3H),1.10(t,J=7.7Hz,3H)、13C NMR (CDCl3,125MHz):206.9,172.3
,145.6,143.3,126.2,125.2,120.5,115.2,91.1,56.8, 47.9,47.3,41.4,40.1,39.5,35.9,28.5,27.2,25.4,9.7、 MS(El)m/z(%):341(33.1), 242(12.2),241(30.6),188(11.1),185(11.0),167(10.8),149(28.3),129(13.2),113(10.0),102(11.2),101(100.0),72(17.6),71(13.6),70(13.5),57(85.0),56(10.7),55(19.3),43(18.2),41(13.8)HRMS(El)C20H23NO4としての計算値:341
.1627、 実測値 341.1628。
50,1726,1626,1505,1436,1155,1030,892,753
1H NMR(CDCl3,600 MHz):6.68(d,J=8.2Hz,1H),6.59(d,J=8.0Hz,10 1H),5.18−5.21(m,1H),4.60(s,1H),3.84(s,3H),3.62(dd,J=13.5,4.6Hz,1H),3.38(m,1H),2.96 (dt,J=13.1,3.8Hz,1H),2.83(dd,J=18.6,6.1Hz,1H),2.55(d,J=18.4Hz,1H),2.34−2.40 (m,1H),2.20−2.33(m,3H),1.81−1.93(m,2H),1.59−1.65(m,2H),1.49−1.58(m.2H),1.13−1.33(m,12),0.81(t,J=6.8Hz,3H)、13C NMR(CDCl3,125MHz):207.3,171.9,145
.6,143.4,126.2,124.9,120.7,115.1,91.3,56.7,47.4,41.3,39.9,39.7,35.7,34.0,33.8,31.9, 31.7,29.5,29.4,28.4,25.6,25.4,25.0,22.7,14.1、MS(El)m/z(%):439(1.0),224(41.8)
,172(10.1),143(36.3),100(15.8),99(56.6),98(36.9),83(18.2),82(11.2),70(21.3),67(10.4),61(52.2),57(19.3),56(100.0),55(43.2),44(14.1),43(46.5),41(42.7)、HRMS (El)C27H37NO4の計算値:439.2723、 実測値439.2719。
2,171.8, 145.9,143.3,126.2,125.2,120.5,115.2, 91.1,56.8,49.4,47.6,47.4,41.4,39.8,35.9,35.7,34.2,34.0,32.1,32.0,29.7,29.6,29.5,25.8,25.4,25.0,22.8,14.3、MS(El)m/z(%):467(2.5),224(21.4),143(17.6),100(10.0),99(27.0),98(17.4),61(23.2),56(100.0),55(19.9),43(20.5),41(19.1)、HRMS(El)C29H41NO4の計算値:467.3036、 実測値467.3037。
実施例3:トロパンアルカロイドのN−アシル化
実施例3a−3e
495,1445,1424,1327,1196,1167,1076,1034、 1H NMR (CDCl3,300MHz):7.29−7.42(m,5H),6.37(s,1H),5.89(s,1H),5.25(t,J=4.8Hz,1H),4.59−4.68(m,1H),4.04−4.13(m,1H),2.22(dt,J=15.3,4.3Hz,1H), 2.05(s,3H),1.78−2.15(m,7
H)ppm、13C NMR (CDCl3,75.5MHz):166.1,165.8,141.8,136.7,123.3,128.2,128.1,127.0,68.3,54.2,50.1,37.3,35.6,28.6,26.9,21.5 ppm、MS (EI)m/z(%)299(18),257(16),168(15),152(28),151(32),136(18),126(10),111(14),110(100),109(38),108(17),103(38),97(10),86(27),84(44),83(15),82(19),81(25),80(29),77(22),71(11),69(33),68(35)67(28),57(19),55(18),47(10),43(68),41(26)、HRMS (EI) C18H21NO3としての計算値:299.1521 、 実測値 299.1518、 元
素分析, C18H21NO3としての計算値: C, 72.22 %、 H, 7.07
%、 実測値: C,70.84%、 H, 7.18%.
4−オキソ−4−(3−オキソ−8−アザ−ビシクロ[3.2.1]オクタン−8−イル)ブタン酸(24)
5,1618,1459,1413,1199,1178、1H NMR(CDCl3,300 MHz):4.95(t,J=5.8Hz,1H),4.52(t,J=5.7Hz,1H),2.65−2.94(m,6H),2.43(t,J=16.5Hz,2H),2.00−2.29(m,2H),1.65−1.92(m,2H)ppm、13C NMR(CDCl3,75.5 MHz):207.1,176.7,168.4,53
.7,51.4,49.4,49.8,29.9,29.0,28.3,27.7 ppm.
無水物のジメチルジカーボネートとの置換
を加えた。室温まで冷却する前に、反応混合物を80℃で18時間加熱し、そしてセライトのプラグを通してろ過した。溶媒を蒸発し、そして残渣をCHCl3中に取り込み、該
有機層を1NのHClで洗浄した。有機層はMgSO4で乾燥し、溶媒を蒸発し、残渣を
フラッシュカラムクロマトグラフィー(CHCl3:MeOH、100:0−>90:1
0)で精製し、25mgの化合物8を、6:4(33%)の比率の2種の異性体の混合物として、無色の油状物として得た。
ルム:3019,2955,2934,2842,2806,1744,1637,1610,1506,1441,1325,1263,1164,1040、1H NMR(
CDCl3,600MHz):6.75(d,J=8.2Hz,2H),6.63−6.
68(m,2H),4.77−4.81(m,1 H),4.67−4.70(m,2H),4.60−4.64(m,1H),4.10(dd,J=13.5,5.0Hz,1H),3.93−3.98(m,1 H),3.92(s,6H),3.80−3.88(m,2H),3.76(s,3H),3.73(s,3H),2.83−2.91(m,2H),2.75−2.82(m, 2H),2.68−2.74(m,2H),2.42−2.48(m,4H),2.34−2.41(m,2H),1.82−2.00(m,4H),1.18−1.28(m,2H)ppm、13C NMR(CDCl3,12
5 MHz):207,2, 155,9,155.5,145.5,143.1,126.1,124.9,124.7,120.4,120.3,114.9,114.8,
91.2,56.7,52.9,52.8,50.9,50.6,47.24,47.17,41.5,41.4,40.7,39.9,39.8,38.01, 37.97,35.0,34.8,28.9,28.5,25.4,25.3 ppm、 HRMS (El) C19H21NO5としての計算値: 343.1420,実測値: 343.1
421.
Claims (42)
- 触媒存在下で、N−メチル化ヘテロ環基質をアシル化反応剤と反応させてモルヒネ誘導体生成物を得ることを含む、ターシャリーN−メチル化ヘテロ環のN−脱メチル化及びN−アシル化のためのワンポット法。
- 前記N−メチル化ヘテロ環はモルヒネアルカロイド、トロパンアルカロイド及びそれらの誘導体からなる群から選択される、請求項1に記載の方法。
- 前記モルヒネアルカロイドはテバイン、オリパビン、14−ヒドロキシコデイノン、14−ヒドロキシモルヒノン、モルヒネ、コデイン、ヒドロモルホン、ヒドロコドン、オキシモルホン、オキシコドン、ヒドロモルホール及びオキシモルホールから成る群から選択される、請求項3に記載の方法。
- 前記モルヒネアルカロイドはヒドロコドンである、請求項4に記載の方法。
- 前記トロパンアルカロイド及びそれらの誘導体はトロピノン、トロパン、トロピン、アトロピン、コカイン及び他のビシクロ−[3.2.1]−アザビサイクリックメチルアミンから成る群から選択される、請求項4に記載の方法。
- 前記無水物は、無水酢酸、イソ−酪酸無水物、n−プロパン酸無水物、デカン酸無水物、ドデカン酸無水物、シクロプロピルカルボニル無水物、シクロブチルカルボニル無水物、炭素原子数1ないし19のカルボン酸から誘導される無水物及びそれらから誘導される混合無水物から成る群より選択される、請求項8に記載の方法。
- 前記無水物は無水酢酸である請求項9に記載の方法。
- 前記ジカーボネートは、炭素原子数1乃至19のアルコールの混合カーボネート誘導体である、請求項11に記載の方法。
- 前記ジカーボネートは、ジメチルジカーボネート、ジ−第三アミルジカーボネート、ジ−第三ブチルジカーボネート、ジアリルピロカーボネート、ジベンジルジカーボネート、ジエチルピロカーボネート、ジメチルジカーボネート、エリトリトールビス(カーボネート)及び混合カーボネートから成る群から選択される、請求項11に記載の方法。
- 前記ジカーボネートはジメチルジカーボネートである、請求項13に記載の方法。
- 前記ジカーボネートはジ−第三ブチルジカーボネートである、請求項13に記載の方法。
- 前記ジカルバミン酸無水物は、N,N’−ジメチルカルバミン酸無水物、N,N’−ジエチルカルバミン酸無水物、ジフェニルカルバミン酸無水物、N,N’−ジフェニル炭酸無水物、N,N’−ジフェニルジ炭酸ジアミド、N,N’−(オキシジカルボニル)ビスグリシンジメチルエステル、ピロール−1−カルボン酸無水物及びそれらの混合物から成る群より選択される、請求項16に記載の方法。
- 前記ジカルバミン酸無水物はN,N’−ジメチルカルバミン酸無水物である、請求項17に記載の方法。
- 前記ジカルバミン酸無水物はN,N’−ジエチルカルバミン酸無水物である、請求項17に記載の方法。
- 前記ジカルバミン酸無水物は、ジフェニルカルバミン酸無水物である、請求項17に記載の方法。
- 前記ジカルバミン酸無水物は、N,N’−ジフェニルジ炭酸ジアミドから成る群から選択される請求項17に記載の方法。
- 前記ジカルバミン酸無水物は、N,N’−(オキシジカルボニル)ビスグリシンジメチルエステルである、請求項17に記載の方法。
- 前記ジカルバミン酸無水物は、ピロール−1−カルボン酸無水物である請求項17に記載の方法。
- 前記金属触媒はPd,Pd(OAc)2、PdCl2、PdCl2(PPh3)4、PdBr2、Pd(acac)2、Pd2(dba)3、Pd(dba)2、Pd(PPh3)4、Cu、Fe、Ru、Co、Rh、Ir、Ni、Pt、Ge、Sn、Os、Cu、Ag、Au、及びPbから成る群から選択される、請求項1に記載の方法。
- 前記触媒は、Cu、Fe、Ru、Co、Rh、Ir、Ni、Pd、Pt、Ge及びSnから成る群から選択される、請求項24に記載の方法。
- 前記触媒は、Os、Cu、Ag、Au、及びPbから成る群から選択される請求項24に記載の方法。
- 前記触媒は、Pd,Pd(OAc)2、PdCl2,PdCl2(PPh3)4、PdBr2,Pd(acac)2、Pd2(dba)3、Pd(dba)2、及びPd(PPh3)4から成る群から選択されるパラジウム触媒である、請求項26に記載の方法。
- 前記パラジウム触媒はPd(OAc)2である請求項27に記載の方法。
- 前記触媒は約0.01当量乃至1.2当量の範囲で存在する、請求項1に記載の方法。
- 前記触媒は約0.01当量乃至0.5当量の範囲で存在する、請求項29に記載の方法。
- 前記触媒は約0.2当量にて存在する、請求項29に記載の方法。
- 前記反応は、少なくとも一種の溶媒存在下で行われる請求項1に記載の方法。
- 前記溶媒は、水、ベンゼン、ジオキサン、トルエン、低級(炭素原子数1乃至4)アルコール及びそれらの混合物から成る群から選択される請求項32に記載の方法。
- 前記少なくとも一種の溶媒はジオキサンである、請求項33に記載の方法。
- 請求項1乃至請求項35のいずれか一項の方法に従い得られるノルヒドロコドン誘導体。
- RがCH3を表す、請求項37に記載の誘導体。
- RがCH(CH3)2を表す、請求項37に記載の誘導体。
- RがCH2CH3を表す、請求項37に記載の誘導体。
- Rが(CH2)8CH3を表す、請求項37に記載の誘導体。
- Rが(CH2)10CH3を表す、請求項37に記載の誘導体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/771,191 | 2007-06-29 | ||
US11/771,191 US7999104B2 (en) | 2007-06-29 | 2007-06-29 | Methods for one-pot N-demethylation/N-acylation of morphine and tropane alkaloids |
PCT/CA2008/001177 WO2009003270A1 (en) | 2007-06-29 | 2008-06-30 | Methods for one-pot n-demethylation/n-acylation of morphine and tropane alkaloids |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010531812A true JP2010531812A (ja) | 2010-09-30 |
JP5462156B2 JP5462156B2 (ja) | 2014-04-02 |
Family
ID=40161388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010513588A Expired - Fee Related JP5462156B2 (ja) | 2007-06-29 | 2008-06-30 | モルヒネ及びトロパンアルカロイドのワンポットn−脱メチル化及びn−アシル化のための方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7999104B2 (ja) |
EP (1) | EP2170897B1 (ja) |
JP (1) | JP5462156B2 (ja) |
KR (1) | KR20100054784A (ja) |
CN (1) | CN101801978B (ja) |
AU (1) | AU2008271862B2 (ja) |
CA (1) | CA2692426C (ja) |
ES (1) | ES2435555T3 (ja) |
IL (1) | IL202993A (ja) |
MX (1) | MX2010000072A (ja) |
NZ (1) | NZ582674A (ja) |
WO (1) | WO2009003270A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014514339A (ja) * | 2011-05-06 | 2014-06-19 | ブロック ユニバーシティ | 金属触媒n−脱メチル化/官能基化および分子内基移動によるモルヒネ類似体の調製のための方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8962841B2 (en) * | 2007-06-29 | 2015-02-24 | Brock University | Methods for one-pot N-demethylation/N-functionalization of morphine and tropane alkaloids |
NZ595591A (en) * | 2009-04-24 | 2013-11-29 | Univ Brock | Processes for the preparation of morphinane and morphinone compounds |
US8623888B2 (en) * | 2009-07-15 | 2014-01-07 | Mallinckrodt Llc | 3-oxy-hydromorphone derivatives |
WO2011154826A1 (en) | 2010-06-11 | 2011-12-15 | Rhodes Technologies | Process for n-dealkylation of tertiary amines |
AU2011263417B2 (en) | 2010-06-11 | 2014-03-27 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof |
PL2601195T3 (pl) | 2010-08-04 | 2014-10-31 | Mallinckrodt Llc | Tandemowy sposób wytwarzania n-alkilomorfinanów |
ES2784690T3 (es) | 2013-12-05 | 2020-09-29 | Univ Bath | Nuevos compuestos opioides y sus usos |
EP3210630A1 (en) * | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
US10626120B2 (en) | 2016-04-22 | 2020-04-21 | Noramco, Llc | N-demethylation of morphinan alkaloids |
US10081636B2 (en) | 2016-07-08 | 2018-09-25 | Cody Laboratories, Inc. | Method for catalytic preparation of hydromorphone, hydrocodone, and other opiates |
CN111646982B (zh) * | 2020-06-04 | 2023-08-08 | 浙江凯普化工有限公司 | 一种去甲酮替芬的合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472253A (en) * | 1981-08-17 | 1984-09-18 | The Florida Board Of Regents On Behalf Of The Florida State University | Process for the preparation of an N-substituted 3-O-alkyl-14-hydroxynormorphinone derivative |
US6388079B1 (en) * | 2000-08-29 | 2002-05-14 | Scinopharm Singapore Pte Ltd. | Process for preparing pergolide |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4613668A (en) * | 1983-12-22 | 1986-09-23 | The United States Of America As Represented By The Department Of Health And Human Services | Short total synthesis or morphinan compounds which uses cyclization of a cycloalkylcarbonyl compound selected from cyclopropylcarbonyl and cyclobutylcarbonyl |
FR2564838B1 (fr) | 1984-05-25 | 1986-11-07 | Sanofi Sa | Procede de dealkylation d'alcaloides et intermediaires |
GB9616253D0 (en) | 1996-08-01 | 1996-09-11 | Johnson Matthey Plc | Preparation of narcotic analgesics |
GB9622516D0 (en) * | 1996-10-29 | 1997-01-08 | Univ Cambridge Tech | Enzymic cofactor cycling |
US6399078B1 (en) | 1998-06-01 | 2002-06-04 | University Of Maryland Biotechnology Institute | Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases |
EP1233966B2 (en) | 1999-11-09 | 2011-10-19 | Abbott Laboratories | Hydromorphinone and hydrocodeinone compositions and methods for their synthesis |
WO2005047291A1 (en) | 2002-11-11 | 2005-05-26 | Mallinckrodt Inc. | Method for the catalytic production of hydrocodone and hydromorphone |
US7323565B2 (en) | 2002-11-11 | 2008-01-29 | Mallinckrodt Inc. | Method for the catalytic production of hydrocodone and hydromorphone |
US6864370B1 (en) | 2003-06-05 | 2005-03-08 | Zhaiwei Lin | Process for manufacturing oxycodone |
EP1871774A1 (en) | 2005-03-28 | 2008-01-02 | Mallinckrodt, Inc. | Method for the catalytic production of hydrocodone, hydromorphone, and derivatives thereof |
-
2007
- 2007-06-29 US US11/771,191 patent/US7999104B2/en not_active Expired - Fee Related
-
2008
- 2008-06-30 EP EP08772837.4A patent/EP2170897B1/en not_active Not-in-force
- 2008-06-30 JP JP2010513588A patent/JP5462156B2/ja not_active Expired - Fee Related
- 2008-06-30 CN CN2008800228063A patent/CN101801978B/zh not_active Expired - Fee Related
- 2008-06-30 MX MX2010000072A patent/MX2010000072A/es active IP Right Grant
- 2008-06-30 KR KR1020107001934A patent/KR20100054784A/ko not_active Application Discontinuation
- 2008-06-30 WO PCT/CA2008/001177 patent/WO2009003270A1/en active Application Filing
- 2008-06-30 AU AU2008271862A patent/AU2008271862B2/en not_active Ceased
- 2008-06-30 NZ NZ582674A patent/NZ582674A/en not_active IP Right Cessation
- 2008-06-30 ES ES08772837T patent/ES2435555T3/es active Active
- 2008-06-30 CA CA2692426A patent/CA2692426C/en not_active Expired - Fee Related
-
2009
- 2009-12-27 IL IL202993A patent/IL202993A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472253A (en) * | 1981-08-17 | 1984-09-18 | The Florida Board Of Regents On Behalf Of The Florida State University | Process for the preparation of an N-substituted 3-O-alkyl-14-hydroxynormorphinone derivative |
US6388079B1 (en) * | 2000-08-29 | 2002-05-14 | Scinopharm Singapore Pte Ltd. | Process for preparing pergolide |
Non-Patent Citations (4)
Title |
---|
JPN6013018550; Tetrahedron Lett. , 1973, 1269-1272 * |
JPN6013018553; Heterocycles 43, 1996, 1403-1414 * |
JPN6013018555; Synlett , 1994, 343-344 * |
JPN6013018558; Chem. Pharm. Bull. 49, 2001, 29-39 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014514339A (ja) * | 2011-05-06 | 2014-06-19 | ブロック ユニバーシティ | 金属触媒n−脱メチル化/官能基化および分子内基移動によるモルヒネ類似体の調製のための方法 |
Also Published As
Publication number | Publication date |
---|---|
US20090005565A1 (en) | 2009-01-01 |
CN101801978B (zh) | 2013-11-06 |
IL202993A (en) | 2014-11-30 |
US7999104B2 (en) | 2011-08-16 |
WO2009003270A1 (en) | 2009-01-08 |
AU2008271862A1 (en) | 2009-01-08 |
CA2692426C (en) | 2015-04-07 |
MX2010000072A (es) | 2010-04-21 |
CA2692426A1 (en) | 2009-01-08 |
EP2170897A4 (en) | 2011-08-24 |
AU2008271862B2 (en) | 2012-07-05 |
JP5462156B2 (ja) | 2014-04-02 |
EP2170897B1 (en) | 2013-08-21 |
EP2170897A1 (en) | 2010-04-07 |
ES2435555T3 (es) | 2013-12-20 |
KR20100054784A (ko) | 2010-05-25 |
NZ582674A (en) | 2012-02-24 |
CN101801978A (zh) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5462156B2 (ja) | モルヒネ及びトロパンアルカロイドのワンポットn−脱メチル化及びn−アシル化のための方法 | |
US9340550B2 (en) | Methods for one-pot N-demethylation/N-functionalization of morphine and tropane alkaloids | |
US4795813A (en) | Synthesis of derivatives of codeine and other 3-O-alkylmorphines | |
AU2008271864B2 (en) | Methods for N-demethylation of morphine and tropane alkaloids | |
JP2012524726A (ja) | モルフィナンおよびモルフィノン化合物の調製法 | |
JP2010531813A (ja) | テバインのモルヒネ誘導体への変換 | |
Carroll et al. | Palladium‐Catalyzed N‐Demethylation/N‐Acylation of Some Morphine and Tropane Alkaloids | |
US9533993B2 (en) | Process for the preparation of morphine analogs via metal catalyzed N-demethylation/functionalization and intramolecular group transfer | |
EP0168686B1 (de) | Verfahren zum N-demethylieren von Morphinan-alkaloiden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130424 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130724 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130809 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130911 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131125 |
|
TRDD | Decision of grant or rejection written | ||
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131125 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140116 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |